Literature DB >> 12784266

Development and testing of the Parkinson's disease quality of life scale.

Mickie Welsh1, Michael P McDermott, Robert G Holloway, Sandy Plumb, Ronald Pfeiffer, Jean Hubble.   

Abstract

We report on the development and results of preliminary psychometric testing of a disease specific health-related quality of life (HRQoL) scale intended for use in individuals diagnosed with idiopathic Parkinson's disease (PD). Results from an initial qualitative study provided content for item development and scale construction of the Parkinson's disease quality of life scale (PDQUALIF). The 33-item instrument includes seven domains: social/role function, self-image/sexuality, sleep, outlook, physical function, independence, and urinary function, plus one item of Global HRQoL. Initial psychometric testing of the instrument was conducted in 233 outpatient clinic attendees with physician-confirmed idiopathic PD. Factor structure, reliability and validity of the scale have been established in this cross-sectional study. Continuing development of the PDQUALIF will be directed at enhancing the psychometric properties, establishing responsiveness and determining appropriateness in culturally diverse samples. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Year:  2003        PMID: 12784266     DOI: 10.1002/mds.10424

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  32 in total

1.  Health-related quality of life as an outcome variable in Parkinson's disease.

Authors:  Pablo Martinez-Martin; Mónica M Kurtis
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

Review 2.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

3.  Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease.

Authors:  M Stacy; R Hauser
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

4.  Fatigue in levodopa-naive subjects with Parkinson disease.

Authors:  G Schifitto; J H Friedman; D Oakes; L Shulman; C L Comella; K Marek; S Fahn
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

Review 5.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Turkish Version Study of "Parkinson's Disease Quality of Life Questionnaire" (PDQL).

Authors:  Elif Elçin Dereli; Ayşe Yaliman; Tuğba Kuru Çolaka; Aycan Çakmak; Arzu Razak Özdinçler; Şule Badilli Demirbaş
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

Review 7.  Physiotherapy for Parkinson's disease: a comparison of techniques.

Authors:  Claire L Tomlinson; Clare P Herd; Carl E Clarke; Charmaine Meek; Smitaa Patel; Rebecca Stowe; Katherine H O Deane; Laila Shah; Catherine M Sackley; Keith Wheatley; Natalie Ives
Journal:  Cochrane Database Syst Rev       Date:  2014-06-17

8.  Interpretation of response categories in patient-reported rating scales: a controlled study among people with Parkinson's disease.

Authors:  Ida Knutsson; Helena Rydström; Jan Reimer; Per Nyberg; Peter Hagell
Journal:  Health Qual Life Outcomes       Date:  2010-06-24       Impact factor: 3.186

9.  Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study.

Authors:  Yaroslav Winter; Sonja von Campenhausen; Julia Gasser; Klaus Seppi; Jens-P Reese; Karl-P Pfeiffer; Kai Bötzel; Wolfgang H Oertel; Richard Dodel; Werner Poewe
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

10.  SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures.

Authors:  Carlos A Brown; Eric M Cheng; Ron D Hays; Stefanie D Vassar; Barbara G Vickrey
Journal:  Qual Life Res       Date:  2009-08-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.